SEARCH

SEARCH BY CITATION

References

  • 1
    Shneider BL. Pediatric liver transplantation in metabolic disease: clinical decision making. Pediatr Transplant 2002; 6: 2529.
  • 2
    Burdelski M. Liver transplantation in metabolic diseases: current status. Pediatr Transplant 2002; 6: 361363.
  • 3
    Asonuma K, Inomata Y, Kasahara M et al. Living related liver transplantation from heterozygote genetic carriers to children with Wilson's disease. Pediatr Transplant 1999; 3: 201205.
  • 4
    Morioka D, Takada Y, Kasahara M et al. Living donor liver transplantation for non-cirrhotic inheritable metabolic liver diseases: impact of the use of heterozygous donors. Transplantation 2005 (in press).
  • 5
    Kasahara M, Kiuchi T, Uryuhara K et al. Treatment of ornithine transcarbamylase deficiency in girls by auxiliary liver transplantation: conceptual changes in living-donor program. J Pediatr Surg 1998; 33: 17531756.
  • 6
    Yorifuji T, Muroi J, Uematsu A, Nakahata T, Egawa H, Tanaka K. Living-related liver transplantation for neonatal-onset propionic acidemia. J Pediatr 2000; 137: 572574.
  • 7
    Kasahara M, Takada Y, Kozaki K et al. Functional portal flow competition after auxiliary partial orthotopic living donor liver transplantation in noncirrhotic metabolic liver disease. J Pediatr Surg 2004; 39: 11381141.
  • 8
    Whitington PF, Alonso EM, Boyle JT et al. Liver transplantation for the treatment of urea cycle disorders. J Inherit Metab Dis 1998; 21(Suppl 1): S112118.
  • 9
    Russo PA, Mitchell GA, Tanguay RM. Tyrosinemia: a review. Pediatr Dev Pathol 2001; 4: 212221.
  • 10
    Matern D, Starzl TE, Arnaout W et al. Liver transplantation for glycogen storage disease types I, III and IV. Eur J Pediatr 1999; 158(Suppl 2): S43S48.
  • 11
    Bove KE, Heubi JE, Balistereri WF, Setchell KDR. Bile acid synthetic defects and liver disease: a comprehensive review. Pediatr Dev Pathol 2004; 7: 315334.
  • 12
    Do KD, Banner BF, Katz E, Szymanski IO, Bonkovsky HL. Benefits of chronic plasmapheresis and intravenous heme-albumin in erythropoietic protoporphyria after orthotopic liver transplantation. Transplantation 2002; 73: 469472.
  • 13
    Morimoto T, Ichiyama M, Tanaka A et al. Guidelines for donor selection and an overview of the donor operation in living related liver transplantation. Transpl Int 1996; 9: 208213.
  • 14
    Fujita S, Kim ID, Uryuhara K et al. Hepatic grafts from live donors: donor morbidities for 470 cases of liver donation. Transpl Int 2000; 13: 333339.
  • 15
    Hauser ER, Finkelstein JE, Valle D, Brusilow SW. Allopurinol-induced orotiduria. A test for mutaions at the ornithine carbamoyltransferase locus in women. N Eng J Med 1990; 322: 16411645.
  • 16
    Arranz JA, Riudor E, Rodes M et al. Optimization of allopurinol challenge: sample purification, protein intake control and the use of orotidine response as a discriminative variable improve performance of the test for diagnosing ornithine carbamoyltransferase deficiency. Clin Chem 1999; 45: 9951001.
  • 17
    Yorifuji T, Muroi J, Uematsu A et al. X-inactivation pattern in the liver of a manifesting female with ornithine transcarbamylase (OTC) deficiency. Clin Genet 1998; 54: 349353.
  • 18
    Egawa H, Oike F, Buhler L et al. Impact of age on outcome of ABO-incompatible living donor liver transplantation. Transplantation 2004; 77: 403411.
  • 19
    Miyagawa-Hayashino A, Haga H, Egawa H et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation 2004; 78: 128135.
  • 20
    Do KD, Banner BF, Katz E, Szymanski IO, Bonkovski HL. Benefits of chronic plasmapheresis and intravenous heme-albumin in erythropoietic protoporphyria after orthotopic liver transplantation. Transplantation 2002; 73: 469472.
  • 21
    Dellon ES, Szczepiorkowski ZM, Dzik WH et al. Treatment of recurrent allograft dysfunction with intravenous hematin after liver transplantation for erythropoietic protoporphyria. Transplantation 2002; 73: 911915.
  • 22
    Van't Hoff WG, Dixon M, Taylor J et al. Combined liver-kidney transplantation in methylmalonic academia. J Pediatr 1998; 132: 10431044.
  • 23
    Bhattacharya N, Heaton N, Rela M, Walter JH, Lee PJ. The benefits of liver transplantation in glycogenosis type Ib. J Inherit Metab Dis 2004; 27: 539540.
  • 24
    Chou JY, Matern D, Mansfield BC, Chen YT. Type I glycogen storage diseases: disorders of the glucose-6-phosphate complex. Curr Mol Med 2002; 2: 121143.
  • 25
    Stankovics J, Crane AM, Andrews E, Wu CH, Wu GY, Ledley FD. Overexpression of human methylmalonic CoA mutase in mice after in vivo gene transfer with asialoglycoprotein/ polylysine/ DNA complexes. Hum Gene Ther 1994; 5: 10951104.
  • 26
    Richard E, Robert E, Cario-Andre M et al. Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug selection. Gene Ther 2004; 11: 16381647.
  • 27
    Broelsch CE, Emond JC, Whitington PF, Thistlethwaite JR, Baker AL, Lichtor JL. Application of reduced-size liver transplants as split grafts, auxiliary orthotopic grafts and living related segmental transplants. Ann Surg 1990; 212: 368375.
  • 28
    Kasahara M, Kaihara S, Oike F et al. Living-donor liver transplantation with monosegments. Transplantation 2003; 76: 694696.
  • 29
    Yersiz H, Renz JF, Farmer DG, Hisatake GM, McDiarmid SV, Busuttil RW. One-hundred in situ split-liver transplantations: a single-center experience. Ann Surg 2003; 238: 496505.
  • 30
    Ito T, Kiuchi T, Egawa H et al. Surgery-related morbidity in living donors of right-lobe liver graft: lessons from the first 200 cases. Transplantation 2003; 76: 158163.
  • 31
    Akabayashi A, Slingsby BT, Fujita M. The first donor death after living-related liver transplantation in Japan. Transplantation 2004; 77: 634.
  • 32
    Plochl W, Spiss CK, Plochl E. Death after transplantation of a liver from a donor with unrecognized ornithine transcarbamylase deficiency. N Engl J Med 1999; 341: 921922.